Serial plasma samples from human volunteers obtained after intravenous administration of Escherichia coli endotoxin were analyzed for the presence of circulating soluble tumor necrosis factor receptors (sTNFR). A four-to fivefold increase of type A (p75) and type B (p55) sTNFR was observed 3 h after endotoxin challenge. Pretreatment of the volunteers with ibuprofen before the injection of endotoxin resulted in a slight increase (3.87±0.2 vs. 3.27±03 ng/ml) and temporal shift of sTNFR-A release concurrent to a marked augmentation of TNF levels (603±118 vs. 338±56 pg/nml) as compared to the group without ibuprofen pretreatment. There was a significant correlation between peak sTNFR-A levels and peak TNF levels in the individual probands (r = 0.52, P = 0.04). On the contrary, release kinetics and plasma concentrations of sTNFR-B were identical in both groups (738±0.69 vs. 7.44±033 ng/ml) and no correlation with individual TNF levels was observed. The amount of sTNFR liberated upon endotoxin challenge was not sufficient to block TNF-mediated cytotoxic effects. Our data indicate that the release in vivo of type A and type B sTNFR upon a short exposure to endotoxin is regulated differently. (J. Clin. Invest. 1992. 90:533-536.)
Introduction
Tumor necrosis factor a/cachectin (TNF)' is a macrophage/ lymphocyte-derived cytokine with a broad spectrum ofimmunoregulatory, metabolic, and proinflammatory activities (1) . Excessive stimulation of TNF-secreting cells by endotoxin leads to a high systemic TNF concentration which is believed to be the main pathogenic factor for hemorrhagic organ failure in septic shock (2) . The vascular brain damage in cerebral malaria is attributed to the activities of TNF as well (3) . In view ofthe pathogenic consequences ofexcessive TNF production, one may expect that the biological activities of TNF are counteracted by serum factors that confine the proinflammatory activities of TNF to the local site of infection and restrict the systemic toxicity of the cytokine.
cancer patients treated with recombinant TNF (6) . The inhibitory proteins bind TNF and lymphotoxin (TNF3); they have been identified as soluble fragments ofthe TNF receptor extracellular domains (sTNFR) (7, 8) . Two types ofTNF receptors with molecular masses of 75 kD (TNFR-A) and 55 kD (TNFR-B) are expressed in cell lines (9, 10) and in tissue ( 11 ) ; synonymous names are TNFRa, TNF-RII, or p75, and TNFR#3, TNF-RI, or p55, respectively. Soluble fragments from both receptor types can be liberated in vitro ( 12) and in vivo (7) . The soluble TNF-binding proteins may be one component of an autocrine and paracrine regulatory system which limits toxic effects of systemically circulating TNF.
Recently we and other investigators have reported the induction of significant levels of circulating TNF by experimental administration ofEscherichia coli endotoxin to healthy volunteers (13) (14) (15) . Pretreatment of the volunteers with ibuprofen, an inhibitor of prostaglandin synthesis, greatly enhanced circulating TNF concentrations (14, 15) while blunting the clinical response to endotoxin. TNF-and IL-1 inhibitory activities were found in several ofthese sera ( 16) suggesting that they have been the cause for the low toxicity observed in this experimental system. Here we report a detailed analysis of sTNFR-A and sTNFR-B in experimental endotoxinemia and compare the formation of sTNFR with the levels of TNF after administration of endotoxin.
Methods
Subjects andstudyprotocol. 21 ( 19) kindly provided by cated concentrations for 30 min and assayed for sTNFR. As seen in Fig. 1 , TNF concentrations up to 10 ng/ml did not interfere with the measurements of sTNFR-A and sTNFR-B. TNF was measured in plasma using a TNF-specific ELISA (Endogen, Inc., Boston, MA) with a detection limit of 10 pg/ml ( 15) . Control experiments with recombinant sTNFR-A and sTNFR-B showed that TNF values, as measured by this assay, were not quenched because ofthe presence of sTNFR: plasma samples taken 90 min p.i. at peak of TNF levels showed identical TNF values with and without exogenous sTNFR-A or sTNFR-B being added at a concentration of up to 20 ng/ml (not shown).
TNF cytotoxicity assay. Purified recombinant sTNFR-A and sTNFR-B expressed in Chinese hamster ovary cells ( 19) 
Results
Intravenous administration ofendotoxin to healthy volunteers caused a marked increase ofsTNFR-A and sTNFR-B (Fig. 2 , B and C) from baseline levels of0.72±0.03 ng/ml and 1.98±0.15 ng/ml, respectively, to peak concentrations of 3.27±0.30 ng/ ml and 7.38±0.69 ng/ml, respectively. In plasma from individuals receiving saline no increase of sTNFR-A or sTNFR-B above baseline levels was observed. Pretreatment with ibuprofen slightly increased sTNFR-A concentrations (3.87±0.21 ng/ml vs. 3.27±0.30 ng/ml, P > 0.001) and caused a 60-min shift in the maximum release of sTNFR-A as compared to individuals without ibuprofen pretreatment (Fig. 2 B) . On the other hand, plasma concentrations and release kinetics of sTNFR-B remained unchanged under the influence of ibuprofen (7.44±0.33 ng/ml vs. 7.38±0.69 ng/ml, Fig. 2 C) . ,reased from 29±4 to 141±9 pmol/liter and cally distinct proteins (9, 10) despite the high sequence homoln 55±10 to 248±11 pmol/liter being always in ogy within the extracellular domain (22) . In this study we demver TNF. We therefore tested whether further onstrate that both types of sTNFR are released into circulation ombinant sTNFR influenced TNF bioactivity in after an i.v. bolus injection ofbacterial endotoxin. The concenndividuals with and without ibuprofen pretreat-trations of both types of sTNFR rise four-to fivefold above lows that recombinant sTNFR-A and sTNFR-B baseline levels reaching their maximum values 180-240 min icentration of 20 ng/ml (660 pmol/liter), i.e., after the injection of endotoxin. sTNFR-B is consistently two imes higher than individual peak levels in our to three times more abundant than sTNFR-A, as detected with 'eakly inhibited the TNF mediated cytotoxicity our standards. A similar predominance of sTNFR-B has been nd 90 min after endotoxin administration. At a found using the same assay also in patients with various maligr concentration ofsTNFR more significant inhi-nancies, except patients with certain B-cell leukemias where )toxicity was observed. The combination of sTNFR-A was the predominant receptor type released into cir-I sTNFR-B showed no stronger inhibition of culation (17) .
-ity than sTNFR-B alone. sTNFR can be liberated from the cell surface of PMN after in vitro stimulation with the chemotactic peptide FMLP, CSa, granulocyte macrophage colony-stimulating factor, and hureral laboratories has demonstrated the presence man PMN elastase, but not with endotoxin, IFN-y, IL-lI, or tory proteins in blood and urine from normal TGF ,B1 ( 12) . The factors that are responsible for the in vivo d from patients with infectious and malignant release of sTNFR have not been identified yet. The ligand TNF 7, 17, 21 ) . TNF inhibitory proteins are derived has been proposed as the physiologic stimulus for the release of (7) from the extracellular domains of two types soluble receptors, since administration of TNF to cancer paors which are biochemically and immunologi-tients was followed by increased sTNFR levels (6, 23). Our results from endotoxinemic individuals indicate a difference in the in vivo induction mechanism for the two types of soluble receptors. The release of sTNFR-A goes in parallel with TNF levels showing an increase and a temporal shift in ibuprofen pretreated individuals. In addition, there is a significant correlation between maximum TNF and maximum sTNFR-A concentrations in the individual probands. However, the increase in sTNFR-A due to ibuprofen pretreatment is much smaller than the concurrent increase in TNF levels. In contrast to sTNFR-A, the maximum secretion and release kinetics for the type B receptor remain unchanged, irrespective of a large increase in TNF production. No correlation between TNF elaboration and sTNFR-B levels could be established suggesting that endogenous TNF is not the primary stimulus for release of the It has been reported that PMN-elastase mediates shedding ;e determinations±SD. of TNFR-A, but not of TNFR-B, from the cell surface of acti-vated PMN in vitro ( 18) . PMN-elastase was also found to be increased in plasma of the ibuprofen pretreated individuals in our experiment ( 15 ) . Our data are consistent with the view that PMN-elastase in serum is responsible for the small increase in sTNFR-A levels, but not sTNFR-B levels, which we observed in ibuprofen pretreated individuals. Furthermore, we notice a clear correlation between maximum PMN-elastase concentrations and sTNFR-A, while no correlation of PMNelastase with sTNFR-B can be established (results not shown). A distinct induction mechanism for release of the two types of sTNFR is not unexpected, since differential TNF receptor expression patterns were found by immunohistochemistry, TNFR-A being mainly expressed in the T cell area and TNFR-B in the germinal center of lymphoid tissue ( 1) . In addition, the expression of the two receptor types in PBL appears to be regulated differentially (22) . In molar terms the maximum concentration of sTNFR produced in response to an endotoxin stimulus is three to eight times higher than the respective TNF concentration (240 pmol/liter vs. 35 pmol /liter). Under the assumption that binding of TNF to sTNFR is a reversible reaction governed by the same equilibrium constant, KD 100 pmol/liter (24) , as binding of TNF to cell surface receptors, we must conclude that a sizable fraction of TNF molecules remains uncomplexed under the conditions of our experiment. This may explain our observation that even higher concentrations of recombinant sTNFR-A and sTNFR-B in plasma exhibit only a minor protective effect on TNF sensitive cells (Fig. 4) . Previous reports also show that inhibition of TNF-mediated cytotoxicity requires a 100-fold molar excess of sTNFR-B over TNF ( 19, 21, 25 ). However, it is possible that one or both sTNFR types exhibit better protection against those TNF-mediated effects that require only a brief exposure to the cytokine. The observation that normal plasma without measurable TNF concentration contains considerable amounts of sTNFR also suggests that the TNF-neutralizing capacity may not be the sole function of sTNFR in circulation. For instance, it is conceivable that sTNFR exerts additional regulatory functions on cells expressing a membrane-anchored form of TNF (26) .
In summary, our results demonstrate that under defined experimental conditions endotoxin first induces the release of TNF into circulation followed by a four-to fivefold increase in sTNFR plasma levels. While secretion of sTNFR-A is apparently related to the release of TNF, the secretion of sTNFR-B seems to be regulated differently. The levels ofsTNFR released into circulation after an endotoxin stimulus are not sufficient to block the preceeding TNF activity entirely, indicating that systemically released sTNFR may have additional functions of biological relevance.
